Poolbeg Pharma PLC (LSE:POLB) — Market Cap & Net Worth
Market Cap & Net Worth: Poolbeg Pharma PLC (POLB)
Poolbeg Pharma PLC (LSE:POLB) has a market capitalization of $729.22K (GBX5.99 Billion) as of June 4, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30566 globally and #855 in its home market, demonstrating a 53.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Poolbeg Pharma PLC's stock price GBX8.50 by its total outstanding shares 705103778 (705.10 Million). Review POLB liabilities breakdown to assess the company's total debt and financial obligations.
Poolbeg Pharma PLC Market Cap History: 2021 to 2026
Poolbeg Pharma PLC's market capitalization history from 2021 to 2026. Data shows change from $815.01K to $729.22K (-4.70% CAGR).
Index Memberships
Poolbeg Pharma PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$951.63 Million | 0.08% | #185 of 722 |
Weight: Poolbeg Pharma PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Poolbeg Pharma PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Poolbeg Pharma PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of POLB by Market Capitalization
Companies near Poolbeg Pharma PLC in the global market cap rankings as of June 4, 2026.
Key companies related to Poolbeg Pharma PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #227 globally with a market cap of $108.72 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $63.77 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #581 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #602 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #227 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.72 Billion | $428.34 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.77 Billion | $618.95 |
| #581 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #602 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Poolbeg Pharma PLC Historical Marketcap From 2021 to 2026
Between 2021 and today, Poolbeg Pharma PLC's market cap moved from $815.01K to $ 729.22K, with a yearly change of -4.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX729.22K | +112.50% |
| 2025 | GBX343.16K | -43.66% |
| 2024 | GBX609.11K | -21.55% |
| 2023 | GBX776.41K | +49.59% |
| 2022 | GBX519.03K | -36.32% |
| 2021 | GBX815.01K | -- |
End of Day Market Cap According to Different Sources
On Jun 4th, 2026 the market cap of Poolbeg Pharma PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $729.22K USD |
| MoneyControl | $729.22K USD |
| MarketWatch | $729.22K USD |
| marketcap.company | $729.22K USD |
| Reuters | $729.22K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more